

L&G PhrmBrkthrhUCITSETF GBP

Fund Information

Sector

Equity - Pharma Health & Biotech

Manager's Name

GO ETF Solutions LLP

Date Manager Appointed

Jan 2018

Launch Date

Jan 2018

Fund Size(£m)

£24.97

Yield* (See page2)

0.00 %

XD Dates

N/A

Last Distribution

N/A (XD Date)

N/A (Pay Date)

N/A(Distribution)

OCF


0.50 %

Fund Aim

The L&G Pharma Breakthrough UCITS ETF (the "ETF") aims to track the performance of the Solactive Pharma Breakthrough Value Index (the "Index").

Sector: Equity - Pharma Health & Biotech

Performance



Morningstar Analyst Rating
N/A

FE Crown Rating

Discrete Performance - 12 months to 31/12/19

	2019	2018	2017	2016	2015
Fund	8.32	-	-	-	-
Stock Sector Average	22.65	-3.36	16.89	-10.80	4.89

Cumulative Performance to 30/09/20

	1 Yr	2 Yrs	3 Yrs	4 Yrs	5 Yrs
Fund	33.62	11.53	-	-	-
Stock Sector Average	19.33	11.37	25.78	42.58	42.59

Performance Analysis - Annualised 3 years

	Growth Rate %	Volatility	Alpha	Beta	Sharpe
Fund	-	-	-	-	-
Stock Sector Average	7.95	15.44	0.00	1.00	0.29

L&G PhrmBrkthrhUCITSETF GBP
Largest Holdings

Holdings	(%)	Holdings	(%)
SEATTLE GENETICS INC	4.22	HORIZON THERAPEUTICS PLC	3.49
BEIGENE LTD	3.86	ULTRAGENYX PHARMACEUTICAL INC	3.48
SWEDISH ORPHAN BIOVITRUM AB	3.63	JAZZ PHARMACEUTICALS PLC	3.47
BASILEA PHARMACEUTICA AG	3.52	KYOWA HAKKO KIRIN CO LTD	3.40
TORII PHARMACEUTICAL CO	3.49	SAREPTA THERAPEUTICS INC	3.39

* Data supplied by fund managers regarding fixed interests funds may not specify yield type. As the provision of redemption yield is an FCA regulatory requirement Novia assumes these are used.

Important Information

Performance details and yields are as at 30/09/2020. Performance figures are inclusive of net reinvested income. Source: FE. This document is designed only for professional investors and experienced advisers. The value of investments and the income gained may fluctuate. Investors may not get back the full amount invested. Past performance is not a guide to the future.